aTYR PHARMA (ATYR) Research & Development (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Research & Development came in at $7.3 million in Q1 2026, down 38.07% YoY from $11.8 million in Q1 2025, and down 32.82% on a QoQ basis from $10.9 million in Q4 2025.
aTYR PHARMA (ATYR) Research & Development (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Research & Development data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Research & Development fell 38.07% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.7 million (up 5.49% YoY) and the FY2025 annual result came in at $60.2 million, up 10.75% from the prior year.
- Research & Development fell to $7.3 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $22.1 million in Q3 2025 to a low of $7.3 million in Q1 2026.
- A 5-year average of $12.2 million and a median of $11.8 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 150.38% — and 2026, when it tumbled 38.07%.
- Tracing ATYR's Research & Development over 5 years: stood at $14.9 million in 2022, then retreated by 14.45% to $12.8 million in 2023, then fell by 4.13% to $12.2 million in 2024, then slipped by 10.93% to $10.9 million in 2025, then plunged by 32.82% to $7.3 million in 2026.
- The last three Research & Development figures came in at $7.3 million (Q1 2026), $10.9 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | aTYR PHARMA | 50.80 Mn | -6.62 Mn | - | 6.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.75 Mn |
| Mar 31, 2026 | 7.32 Mn |
| Dec 31, 2025 | 10.89 Mn |
| Sep 30, 2025 | 22.13 Mn |
| Jun 30, 2025 | 15.38 Mn |
| Mar 31, 2025 | 11.81 Mn |
| Dec 31, 2024 | 12.23 Mn |
| Sep 30, 2024 | 14.81 Mn |
| Jun 30, 2024 | 13.97 Mn |
| Mar 31, 2024 | 13.36 Mn |
| Dec 31, 2023 | 12.76 Mn |
| Sep 30, 2023 | 10.32 Mn |
| Jun 30, 2023 | 9.84 Mn |
| Mar 31, 2023 | 9.38 Mn |
| Dec 31, 2022 | 14.91 Mn |
| Sep 30, 2022 | 9.87 Mn |
| Jun 30, 2022 | 9.14 Mn |
| Mar 31, 2022 | 8.90 Mn |
| Dec 31, 2021 | 5.96 Mn |
| Sep 30, 2021 | 5.14 Mn |